Year: 2025
Type: article
Abstract: Description Skin cancer remains a significant health concern, affecting approximately 1 in 5 Americans over their lifetime. In 2024 alone, an estimated 100,640 new cases are projected, contributing to roughly 5% of all cancer diagnoses. While malignant melanoma accounts for a smaller proportion of cases, its aggressive nature and high metastatic potential make it particularly challenging to manage. This study investigates the potential of UBASH3B gene knockout as a therapeutic strategy to inhibit tumor growth and metastasis. UBASH3B has emerged as a critical regulator of cancer progression, with its expression linked to enhanced tumor cell invasion and dissemination. Using CRISPR-Cas9-mediated gene knockout in A375 melanoma cells, UBASH3B was effectively silenced. Knockout efficacy was validated using an indel detection assay to confirm CRISPR-induced mutations at the target site, followed by real-time PCR to confirm minimal to no UBASH3B expression post-knockout. These findings support UBASH3B as a promising therapeutic target for inhibiting melanoma progression and warrant further investigation across other cancer types. Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Source: The Journal of Immunology
Authors: Elizabeth F. Elliot, Gina A. Rubiano, Roberto Aguilar
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funder: National Institutes of Health
Awards: G9000018991, G9000311330
OpenAlex ID: W4416449480
FWCI:
Cites:
Cited by:
Related to: